Percutaneous Coronary Intervention News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Teleflex (TFX) Announces 510(k) Clearance and U.S. Launch of Spectre(TM) Guidewire
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and U.S. commercial launch ... Devices, Interventional, Cardiology, FDA, Product Launch Teleflex, Spectre Guidewire, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2017 Category: Pharmaceuticals Source Type: news

New Study Finds Abiomed Impella(R) Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention
DANVERS, Mass., March 09, 2017 -- (Healthcare Sales & Marketing Network) -- A new study published in Circulation Research finds use of hemodynamic support with Impella® 2.5 heart pump during high-risk percutaneous coronary intervention (HRPCI) can redu... Devices, Interventional, Cardiology Abiomed, Impella, Heart Pump, percutaneous coronary intervention (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2017 Category: Pharmaceuticals Source Type: news

Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk
Shorter percutaneous coronary intervention (PCI) procedures are associated with an increased risk of acute stent thrombosis (AST) in patients treated with bivalirudin, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2017 Category: Consumer Health News Tags: Emergency Medicine News Source Type: news

Daiichi Sankyo begins enrolment in Phase IIIb trial of edoxaban to treat atrial fibrillation
Japanese-based pharmaceutical firm Daiichi Sankyo has begun enrolment in the Phase IIIb ENTRUST-AF PCI clinical trial of edoxaban for the treatment of atrial fibrillation patients who have undergone percutaneous coronary intervention (PCI) with stent … (Source: Drug Development Technology)
Source: Drug Development Technology - March 7, 2017 Category: Pharmaceuticals Source Type: news

Radial access, same-day cardiac procedure could save $300 million annually
(American College of Cardiology) If hospitals can perform more transradial, same-day percutaneous coronary intervention, or PCIs, not only will patients benefit because it is associated with have less complications, but collectively, hospitals across the U.S. could save $300 million each year, according to research published today in JACC: Cardiovascular Interventions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news

Medtronic launches Signia stapler
Medtronic (NYSE:MDT) said today it launched its Signia stapling system in the US, Western Europe and Japan. The newly launched stapler from the Fridley, Minn.-based company includes Adaptive Firing technology which adjusts the stapler’s speed based on tissue variability measurements for more consistent staple lines. The device also includes 1-hand staple firing to allow for more operator freedom during procedures. “In my experience to date, I believe the articulation, rotation and firing of the Signia system provides an important new option in the performance of minimally invasive surgical procedures. Its abili...
Source: Mass Device - February 16, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Surgical Medtronic Source Type: news

MassDevice.com +5 | The top 5 medtech stories for February 12, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. AcelRx touts Dsuvia data for burn victims AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or ...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

MassDevice.com +5 | The top 5 medtech stories for February 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. AcelRx touts Dsuvia data for burn victims AcelRx Pharmaceuticals said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or ...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic launches DxTerity, TRA-line of radial access devices for PCIs
Medtronic (NYSE:MDT) today announced a slew of new percutaneous coronary intervention devices it added to its portfolio, including the DxTerity diagnostic angiography catheter line, the DxTerity TRA, InTRAkit transradial devices and the TRAcelet compression device. The Fridley, Minn.-based company said all of the items have already received FDA clearance in the US and CE Mark approval in the European Union for use in diagnostic cardiac catheterization procedures and percutaneous coronary interventions. Medtronic’s DxTerity and DxTerity TRA diagnostic catheters are designed to help determine whether revascularization...
Source: Mass Device - February 13, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Medtronic Source Type: news

Abiomed gains after Abbott tables HeartMate PHP program
Abiomed (NSDQ:ABMD) shares closed up more than 5% yesterday as investors reacted to reports that Abbott (NYSE:ABT) paused its HeartMate PHP program in Europe. Abbott, which acquired the Thoratec line of HeartMate cardiac assist devices when it paid $25 billion for St. Jude Medical (NYSE:STJ) last month, reportedly advised physicians last week that it’s temporarily halting its Shield II clinical trial for the HeartMate PHP pump due to an issue with its catheter. Abbott said it “temporarily paused the HeartMate PHP Shield II IDE clinical trial as well as shipment and implantation of the device for commercia...
Source: Mass Device - February 7, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Wall Street Beat Abbott Abiomed Inc. Source Type: news

Ticagrelor More Effective Than Clopidogrel in Some Cardiac Arrest Survivors Ticagrelor More Effective Than Clopidogrel in Some Cardiac Arrest Survivors
In comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention (PCI) and hypothermia, ticagrelor results in faster and stronger platelet inhibition compared to clopidogrel, researchers in Slovenia say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 30, 2016 Category: Consumer Health News Tags: News Source Type: news

PCI Thrombus Aspiration Might Help Some PCI Thrombus Aspiration Might Help Some
Pooled data indicate that thrombus aspiration reduces cardiovascular mortality in certain patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 27, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Elective Surgery Delay After PCI May Be Safely Shortened Elective Surgery Delay After PCI May Be Safely Shortened
More than a month after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES), patients undergoing elective surgery appear to be at no greater risk than those without ischemic heart disease, according to Danish researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 21, 2016 Category: Surgery Tags: General Surgery News Source Type: news

Bayer ’s Xarelto® Significantly Reduced Bleeding Compared to VKA in AF-Patients also Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention (for specialized target groups only)
PIONEER AF-PCI is the first randomised study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Data were presented in a late-breaking clinical trial session at AHA and published simultaneously in The New England Journal of Medicine (Source: Bayer Company News)
Source: Bayer Company News - November 14, 2016 Category: Pharmaceuticals Source Type: news

Phase 3b Study Shows Significantly Less Bleeding with XARELTO ® (rivaroxaban) Compared to Warfarin in People with Non-Valvular Atrial Fibrillation Following Percutaneous Coronary Intervention with Stenting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 14, 2016 Category: Pharmaceuticals Source Type: news